J. Silvio Gutkind, PhD
J. Silvio Gutkind has pioneered work on the potent oncogenic activity of G proteins and GPCR, which has led to novel strategies for treating and preventing several types of cancer. He has published more than 400 original studies in prestigious journals, and has organized and co-organized multiple national and international meetings and symposia on signal transduction and oral cancer research. Dr. Gutkind received his PhD in pharmacy and biochemistry from the University of Buenos Aires, Argentina, and trained as a post-doctoral fellow at the National Institute of Mental Health and the National Cancer Institute. His research team studies the molecular basis of cancer, with emphasis on basic mechanisms of signal transduction and cell growth control and their dysregulation in cancer, with emphasis on oral squamous cell carcinogenesis, AIDS-malignancies, and uveal and cutaneous melanoma. Dr. Gutkind has recently led a multi-institutional effort aimed at exploring the biochemical consequences and clinical benefits of treating newly diagnosed head and neck cancer patients with mTOR inhibitors. As part of a multidisciplinary team at Moores Cancer Center, he is now investigating the effectiveness and mechanism of action of PI3K/mTOR inhibitors for oral cancer prevention and treatment, both as single agents and as part of novel co-targeting strategies, and he is co-leading a new precision prevention medicine trial in oral premalignancy. Read full profile.